Hormonal
Tirzepatide, a dual GLP-1 and GIP agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity and body weight in patients with moderate-to-severe OSA and obesity, marking the first FDA-approved pharmacotherapy for this condition.
If you have moderate-to-severe sleep apnea and obesity, tirzepatide is a new, FDA-approved option. It is a once-weekly injection that helps you lose significant weight (16-17%) and reduces your sleep apnea severity (AHI) by 20-24 events per hour. While it may cause temporary stomach issues, it offers a dual benefit for both your sleep and metabolic health.
In December 2024, tirzepatide, a once‑weekly, injectable dual GLP‑1 and GIP agonist, became the first FDA‑approved pharmaceutical for OSA treatment, as a result of findings from the SURMOUNT‑OSA trial... Across both trials, tirzepatide led to an average reduction in AHI by 20–24 events/hour at 52 weeks... Patients taking tirzepatide in both trials had a 16–17% reduction in body weight
Why this rating
Based on the SURMOUNT-OSA trial, a double-blind, randomized controlled trial across nine countries.
Source
Obstructive Sleep Apnea: An Evolving Therapeutic Landscape with an Emerging Role for Incretin-Based Therapies
Bugao Xu et al. · Advances in Therapy · 2025
DOI 10.1007/s12325-025-03312-6
More from this paper
- Positive Airway Pressure (PAP) therapy, while effective for reducing AHI and improving symptoms, has not demonstrated a benefit on composite cardiovascular endpoints in randomized controlled trials.Good
- Weight loss, achieved through lifestyle changes, medications, or bariatric surgery, is associated with significant improvements in OSA severity, with a 20% BMI reduction leading to an average 57% decrease in AHI.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →